Apigenin as neuroprotective agent: Of mice and men. (February 2018)

• Record Type: Journal Article
• Authors: Nabavi, Seyed Fazel; Khan, Haroon; D'onofrio, Grazia; Šamec, Dunja; Shirooie, Samira; Dehpour, Ahmad Reza; Argüelles, Sandro; Habtemariam, Solomon; Sobarzo-Sanchez, Eduardo
• Is Part Of: Pharmacological research. Volume 128(2018)
• Page Start: 359
• Page End: 365
• Publication Date: 2018-02
• Subjects: Neuroprotection -- Alzheimer's disease -- Parkinson's disease -- Apigenin -- Flavonoids; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2017.10.008
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Neurodegenerative disorders (NDDs) such as Alzheimer's and Parkinson's diseases are the most common age-related pathologies that affect millions of people all over the world. To date, effective therapy for NDDs is not available and current approaches to disease management include neuroprotection strategy with a hope of maintaining and enhancing the function of survising neurons. Of course, such an approach by its own will not offer a cure but is likely to delay the disease progression by ameliorating the increase of neurotoxic agents such reactive oxygen species (ROS) as well as the associated inflammatory cascades. In this regard, natural products including flavonods that offer neuroprotection through multiple mechanisms have gained a lot of interest in recent years. In this communication, evidences from the various experimental models and clinical trials on the therapeutic potential of one promising flavonod, apigenin, is presented. Its chemistry, mechanism of action and potential benefits in the various examples of NDDs are discussed in the light of drug discovery aspects.